Alphamab Oncology Shareholders Approve Key Resolutions

Alphamab Oncology (HK:9966) has released an update.

Alphamab Oncology has announced successful passage of all proposed resolutions at its Annual General Meeting held on June 12, 2024, with overwhelming shareholder approval. Key resolutions included the re-election of board members, authorization for the company to repurchase and issue shares, and the reappointment of Deloitte Touche Tohmatsu as auditors. These strategic approvals signal strong shareholder confidence and pave the way for the company’s future initiatives.

For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.